Commerce Bank Sells 440 Shares of Artivion, Inc. (NYSE:AORT)

Commerce Bank reduced its position in Artivion, Inc. (NYSE:AORT) by 3.1% in the third quarter, HoldingsChannel.com reports. The firm owned 13,700 shares of the company’s stock after selling 440 shares during the period. Commerce Bank’s holdings in Artivion were worth $365,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. nVerses Capital LLC bought a new position in Artivion in the 2nd quarter worth $28,000. RiverPark Advisors LLC bought a new position in shares of Artivion in the second quarter worth about $55,000. RW Investment Management LLC purchased a new stake in shares of Artivion during the second quarter worth about $219,000. Intech Investment Management LLC bought a new stake in Artivion during the 2nd quarter valued at approximately $253,000. Finally, Tidal Investments LLC purchased a new position in Artivion in the 1st quarter worth approximately $257,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Price Performance

Artivion stock opened at $28.66 on Wednesday. Artivion, Inc. has a 52-week low of $16.48 and a 52-week high of $30.00. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The firm’s fifty day moving average is $26.68 and its 200 day moving average is $25.66. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -1,433.00 and a beta of 1.75.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AORT shares. JMP Securities initiated coverage on shares of Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price objective for the company. Oppenheimer lifted their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Artivion in a research note on Friday, September 27th. Finally, Stifel Nicolaus lifted their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $31.00.

Insider Activity

In other news, CAO Amy Horton sold 12,430 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. The trade was a 8.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.